Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Improving the patient's experience of IVF/ICSI: A proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment

Paul Devroey*, Mohamed Aboulghar, Juan Garcia-Velasco, Georg Griesinger, Peter Humaidan, Efstratios Kolibianakis, William Ledger, Candido Tomás, Bart C.J.M. Fauser

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Patients undergoing IVF/ICSI frequently experience substantial treatment burden, risk and psychological distress. These three related elements contribute to a negative patient experience that can lead to treatment discontinuation if pregnancy is not achieved. One approach to minimize these factors is the use of protocols designed to achieve high term, singleton birth rates per IVF treatment started, while improving the patient's welfare. Gonadotrophin-releasing hormone (GnRH) antagonists may be suitable for inclusion in such a protocol. In clinical trial data and meta-analyses, treatment with these agents is associated with similar live birth rates but reduced treatment burden (duration and side effects) and less risk of ovarian stimulation syndrome, compared with GnRH agonist long protocols. GnRH antagonists may also be associated with reduced psychological distress compared with agonists, but so far, the evidence for this is inconclusive. To facilitate the implementation of treatments that optimize the patient's experience, a simple GnRH antagonist protocol for use in predicted normal responders is proposed.

OriginalspracheEnglisch
ZeitschriftHuman Reproduction
Jahrgang24
Ausgabenummer4
Seiten (von - bis)764-774
Seitenumfang11
ISSN0268-1161
DOIs
PublikationsstatusVeröffentlicht - 04.2009

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Fingerprint

Untersuchen Sie die Forschungsthemen von „Improving the patient's experience of IVF/ICSI: A proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren